TY  - JOUR
AU  - Baccelli, Irène
AU  - Stenzinger, Albrecht
AU  - Vogel, Vanessa
AU  - Pfitzner, Berit Maria
AU  - Klein, Corinna
AU  - Wallwiener, Markus
AU  - Scharpff, Martina
AU  - Saini, Massimo
AU  - Holland-Letz, Tim
AU  - Sinn, Hans-Peter
AU  - Schneeweiss, Andreas
AU  - Denkert, Carsten
AU  - Weichert, Wilko
AU  - Trumpp, Andreas
TI  - Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients.
JO  - OncoTarget
VL  - 5
IS  - 18
SN  - 1949-2553
CY  - [S.l.]
PB  - Impact Journals LLC
M1  - DKFZ-2017-00231
SP  - 8147 - 8160
PY  - 2014
AB  - Although luminal-type primary breast cancer can be efficiently treated, development of metastatic disease remains a significant clinical problem. We have previously shown that luminal-type circulating tumor cells (CTCs) co-expressing the tyrosine-kinase MET and CD47, a ligand involved in cancer cell evasion from macrophage scavenging, are able to initiate metastasis in xenografts. Here, we investigated the clinical relevance of MET-CD47 co-expression in 255 hormone receptor positive breast tumors by immunohistochemistry and found a 10.3- year mean overall-survival difference between MET-CD47 double-positive and double-negative patients (p<0.001) MET-CD47 co-expression defined a novel independent prognosticator for overall-survival by multivariate analysis (Cox proportional hazards model: HR: 4.1, p<0.002) and CD47 expression alone or in combination with MET was strongly associated with lymph node metastasis. Furthermore, flow cytometric analysis of metastatic patient blood revealed consistent presence of MET+CD47+ CTCs (range 0.8 - 33.3
KW  - Antigens, CD47 (NLM Chemicals)
KW  - Biomarkers, Tumor (NLM Chemicals)
KW  - CD47 protein, human (NLM Chemicals)
KW  - MET protein, human (NLM Chemicals)
KW  - Proto-Oncogene Proteins c-met (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:25230070
C2  - pmc:PMC4226673
DO  - DOI:10.18632/oncotarget.2385
UR  - https://inrepo02.dkfz.de/record/119599
ER  -